N-trityl-serine | 131797-08-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: N-trityl-serine
• 英文别名: N-Trityl-serin；N-(triphenylmethyl) serine；3-hydroxy-2-(tritylazaniumyl)propanoate
• CAS: 131797-08-5
• 化学式: C₂₂H₂₁NO₃
• 分子量: 347.414
• InChiKey: CAXCRXDCRBCENL-UHFFFAOYSA-N

物化性质

• 熔点：
  180 °C
• 沸点：
  548.6±50.0 °C(Predicted)
• 密度：
  1.224±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-trityl-serine 、 3-phenyl-4-sydnonecarboxylic acid chloride 在 吡啶 作用下， 以 乙酸乙酯 为溶剂， 生成 4-(2-carboxy-2-tritylamino-ethoxycarbonyl)-3-phenyl-sydnone
  参考文献：
  名称：

  Zotova,S.A. et al., Journal of Organic Chemistry USSR (English Translation), 1966, vol. 2, p. 729 - 732

  摘要：

  DOI：
• 作为产物：
  描述：

  N-trityl-DL-serine ethyl ester 生成 N-trityl-serine
  参考文献：
  名称：

  Amiard et al., Bulletin de la Societe Chimique de France, 1955, p. 191

  摘要：

  DOI：

文献信息

• MELANIN PRODUCTION INHIBITOR
  申请人：Yokoyama Kouji

  公开号：US20110243865A1

  公开（公告）日：2011-10-06

  Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor comprises a compound represented by general formula (1) (excluding clotrimazole), and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent, wherein at least one of A1, A2 and A3 is selected from the aryl group and the aromatic heterocyclic group, the total number of carbon atoms contained in A1, A2 and A3 is 6 to 50 and, when at least two of A1, A2 and A3 represent the aryl groups or the aromatic heterocyclic groups, the adjacent two aryl or aromatic heterocyclic groups may be bound to each other via an alkyl chain or an alkenyl chain to form a ring; m represents an integer of 0 to 2; X represents a hetero atom, a hydrogen atom, or a carbon atom; R1 and R2 are independently selected from a hydrogen atom and an oxo group, wherein when one of R1 and R2 is an oxo group, the other is not present; and R3 is selected from a hydrogen atom, and a C 1-8 hydrocarbon group in which one or some of hydrogen atoms or carbon atoms may be substituted by a hetero atom or hetero atoms, wherein the number of R3's present in the compound corresponds to the number of X's and, when two or more R3's are present, the R3's are independently present and the adjacent two R3's may be bound to each other to form, together with X, a ring, and the terminal of R3 may be bound to a carbon atom to which A1, A2 and A3 are bound, thereby forming a ring.

  披露了一种黑色素生产抑制剂，它对黑色素的生产具有出色的抑制活性且高度安全。该黑色素生产抑制剂包括由通用公式（1）表示的化合物（不包括克霉唑）和/或其药理上可接受的盐。在公式中，A1、A2和A3独立地选自氢原子、可能带有取代基的芳基团和可能带有取代基的芳香杂环团，其中至少A1、A2和A3之一选自芳基团和芳香杂环团，A1、A2和A3中包含的碳原子总数为6至50，并且当至少两个A1、A2和A3表示芳基团或芳香杂环团时，相邻的两个芳基或芳香杂环团可以通过烷基链或烯基链相互连接形成环；m代表0至2的整数；X代表异原子、氢原子或碳原子；R1和R2独立地选自氢原子和氧代基，其中当R1和R2之一是氧代基时，另一个不出现；R3选自氢原子和C 1-8 碳氢化合物组，其中一些或所有的氢原子或碳原子可能被异原子或异原子取代，其中化合物中存在的R3的数量对应于X的数量，并且当存在两个或更多R3时，R3独立地存在，并且相邻的两个R3可以相互连接以与X一起形成环，并且R3的末端可以与A1、A2和A3连接的碳原子结合，从而形成环。
• [EN] PHOSPHONATE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS DE PHOSPHONATE POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035417A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I''' or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  提供含有公式I、I"和I'''或其药物可接受的盐或组合物的补体因子D抑制剂的化合物、使用方法和制备过程。本文所述的抑制剂针对因子D并抑制或调节补体级联。本文所述的因子D抑制剂减少了补体的过度激活。
• Intermediate compounds and their use in preparation of lacosamide
  申请人：Madhra Mukesh Kumar

  公开号：US08378142B2

  公开（公告）日：2013-02-19

  The present invention is concerned with novel compounds and their use for the preparation of lacosamide. The present invention also contemplates processes for the preparation of lacosamide employing the novel compound of general Formula II, Formula IIa or Formula IIb as intermediate. Wherein R1 is —OH or —OMe; R2 is —OH or —NH—CH2—C6H5.

  本发明涉及新化合物及其用于制备拉科萨胺的用途。本发明还考虑使用一般式II、IIa或IIb的新化合物作为中间体制备拉科萨胺的过程。 其中，R1为—OH或—OMe；R2为—OH或—NH—CH2—C6H5。
• PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF LACOSAMIDE
  申请人：Madhra Mukesh Kumar

  公开号：US20130085304A1

  公开（公告）日：2013-04-04

  The present invention relates to processes for the preparation of crystalline polymorphic forms of lacosamide (Formula I), including processes for inter-conversion among such polymorphic forms.

  本发明涉及制备拉科萨米德（式I）的晶态多型形式的过程，包括多种多型形式之间的互相转化过程。
• Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents
  申请人：Kohn Harold L.

  公开号：US20110021482A1

  公开（公告）日：2011-01-27

  A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula I or Ia: or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.

  本发明的第一个方面是公式I或Ia的化合物（有时也在此处称为“活性剂”或“活性化合物”）：或其药学上可接受的盐或前药。还描述了其组成物和使用方法（例如用于治疗神经系统疾病）。